Prostate cancer-specific mortality rate dropping in France

An article in Progrès en urologie states that the prostate cancer-specific mortality rate in France has been dropping by 2.5 percent per year.

Audenet and Rouprêt note that in France — as in America — prostate cancer is the second leading cause of cancer-specific deaths among men.

They argue that:

  • The major therapeutic options are still surgery, radiotherapy, and androgen deprivation therapy (ADT) — either alone or in combination.
  • The combination of radiation therapy with ADT is the French “gold standard” of therapy (although we suspect others might not agree with that statement).
  • The improvements in available diagnostic tools are allowing a more personalized management of prostate cancer patients.
  • The development of newer prognostic factors (early PSA assay, time to reach PSA nadir) is contributing to provide better patient diagnosis and monitoring.
  • Technical advances in surgery and radiotherapy, along with new methods of androgen suppression, should continue this trend.

One Response

  1. I definitely agree with the French “gold standard” of radiation therapy (external) with ADT. That was how my prostate cancer was treated over 7 years ago and there is no sign of recurrence yet.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: